New Study Shows Potential Benefits of Screening All New Cancer Patients for Hepatitis

January 17, 2019, USA: “Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices" By Scott D. Ramsey, MD, PhD; Joseph M. Unger, PhD; Laurence H. Baker,DO; et al This study of 3051 patients attempted to determine the prevalence of chronic hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly-diagnosed cancer. It found 0.6% p...

Hologic Obtains Canadian Approval for Aptima® Hepatitis C and B Quant Assays

MARLBOROUGH, Mass., Nov. 10, 2016 /CNW/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has obtained approval from Health Canada for the Company's hepatitis C and B assays. The Aptima® HCV and HBV Quant assays are nucleic acid amplification tests for the quantitative detection of RNA from hepatitis C, and DNA from hepatitis B-infected patients.  These assays supplement the already available Aptima HIV-1 Quant assay, rounding out the Company's vir

UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C

GENEVA - UNITAID today announced a partnership with FIND to improve diagnostics and treatments for hepatitis C virus (HCV) and make them more affordable and widely available to those in need. The US $38.3 million project will support the development of better, simpler,  diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Ma

APRI

AST to Platelet Ratio Index (APRI)   APRI above 1.5 can indicate advanced HCV liver damage. WARNING:  Do NOT use APRI alone as its accuracy rate is not sufficient to do so; experts recommend using a combination of two or  all three of the non-invasive liver tests (APRI, FibroSure/FibroTest, or FibroScan). Using the results of APRI, a non-invasive test, one can very roughly determine whether one has a high risk of having advanced live

Fibroscan

FibroScan Alternative to Biopsy   Echosens™ Machine FIBROSCAN (also known as transient elastography, a technology developed by Echosens™ of Paris, France) poses the greatest competition to biopsy as it is non-invasive, less expensive, and (arguably) equally accurate in measuring degree of liver inflammation and fibrosis, particularly in the higher end of the Metavir scale (Stages 3 and 4).   Below you will find a Co